¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acute parenchymatous hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® hepatitis ÇÑ±Û °£¿°
¼³¸í   
  °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿­-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ­ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁֵȠ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°À̸砱נ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀΠ°Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼­ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù À̻󠰣¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇϴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇϴ ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼­ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª È¯ÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼­ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î È¯ÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, È¯ÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁַΠ°¡À»¿¡¼­ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í Ã»¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼­´Â È²´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿­(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿­µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà¶§µµ ÀÖ¾î Ã³À½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼­¼­È÷ ¹ßº´Çϴ °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í È²´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ È²´ÞÀÌ ³ªÅ¸³­´Ù. È²´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼­ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈ­ÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇϴ Àü°Ý¼º°£¿°À̶ó°í Çϴ °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú ÁߠȲ´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í Çϴ °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϴ °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈ­Çϱ⠽±´Ù.
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
¿µ¹® fulminant hepatitis ÇÑ±Û Àü°Ý°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º È²»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç È¯Àڴ º¸Åë »ç¸ÁÇÑ´Ù. È²´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ À̹̠Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© È²´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿­À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇϴ ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇϰԠµÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇϴ °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼­ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, Æ¯È÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù.
¿µ¹® acute appendicitis ÇÑ±Û ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
¼³¸í   
  ¿Ü°úÀû Ã³Ä¡¸¦ ¿äÇϴ ¸·Ã¢ÀÚ²¿¸®(Ãæ¼ö)ÀÇ ±Þ¼º¿°ÁõÀ¸·Î¼­, º¸Åë ÇϺ¹ºÎÀÇ ¿À¸¥ÂÊ 1/4 ºÎÀ§¿¡¼­ÀÇ ÅëÁõÀ̠Ư¡À̸ç, ±¹¼Ò¾ÐÅë, ±ÙÀ°±äÀå ÇǺΰ¨°¢ÀÇ °ú¹Î µîÀ» ¼ö¹ÝÇÑ´Ù. ÀϹݵòµéÀÌ ¡°¸ÍÀå¿°¡±À̶ó°í Çϴ °ÍÀ¸·Î ¸ÍÀå¿°Àº ¸·Ã¢ÀÚÀÇ ¿°ÁõÀ¸·Î ±¸º°µÇ¾î¾ß ÇÑ´Ù. ¹ß¿­°ú ´ÙÇü¹éÇ÷±¸Áõ´Ù´Â ±¹¼Ò°¨¿°ÀÇ °á°úÀÌ´Ù. ¸·Ã¢ÀÚ²¿¸®ÀÇ À§Ä¡-À¯Âø»óÅÂ-²¿ÀÓ µî¿¡ ÀÇÇØ Áõ»ó°ú Â¡ÈĴ º¯µ¿µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute hepatitis
    ±Þ¼º°£¿°
  • parenchymatous cartilage
    ¼¼Æ÷¿¬°ñ
  • parenchymatous degeneration
    ½ÇÁúº¯¼º
  • parenchymatous keratitis
    ½ÇÁú°¢¸·¿°
  • parenchymatous mastitis
    ½ÇÁúÀ¯¹æ¿°
  • parenchymatous myositis
    ½ÇÁú±Ù(À°)¿°
  • parenchymatous nephritis
    ½ÇÁúÄáÆÏ¿°, ½ÇÁú½ÅÀå¿°
  • parenchymatous organ
    ½ÇÁú±â°ü
  • parenchymatous salpingitis
    ½ÇÁúÀڱðü¿°, ½ÇÁú³­°ü¿°
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª°£¿°
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • cholangiolitic hepatitis
    ¾µ°³¼¼°ü¿°¼º°£¿°, ´ã¼¼°ü¿°¼º°£¿°
  • cholestatic hepatitis
    ¾µ°³ÁóÁ¤Ã¼°£¿°, ´ãÁóÁ¤Ã¼°£¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute hepatitis
    ±Þ¼º°£¿°
  • hepatitis
    °£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • acute
    ±Þ¼º-
  • acute appendicitis
    ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
  • acute pulmonary atelectasis
    ±Þ¼º¹«±âÆó
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute cholecystitis
    ±Þ¼º¾µ°³¿°
  • acute acalculous cholecystitis
    ±Þ¼º¹«°á¼®¾µ°³¿°
  • acute emphysematous cholecystitis
    ±Þ¼º°ø±âÁõ¾µ°³¿°, ±Þ¼º°ø±âÁõ´ã³¶¿°
  • acute febrile episode
    ±Þ¼º¿­¼º¹ÝÀÀ
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü(Áõ)
  • acute transverse myelitis
    ±Þ¼ºÈ¾´Üô¼ö¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • parenchymatous cartilage
    (¢¡cellular cartilage) ¼¼Æ÷¿¬°ñ
  • parenchymatous degeneration
    ½ÇÁúº¯¼º
  • parenchymatous keratitis
    ½ÇÁú°¢¸·¿°
  • parenchymatous mastitis
    ½ÇÁúÀ¯¹æ¿°
  • parenchymatous myositis
    ½ÇÁú±ÙÀ°¿°
  • parenchymatous nephritis
    ½ÇÁúÄáÆÏ¿°
  • parenchymatous organ
    ½ÇÁú±â°ü
  • parenchymatous salpingitis
    (¢¡pachysalpingitis) ºñÈÄÀڱðü¿°
  • acute
    ±Þ¼º-
  • acute exposure
    ±Þ¼ºÇÇÆø, ±Þ¼º³ëÃâ
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute anxiety neurosis
    ±Þ¼ººÒ¾È½Å°æÁõ
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute catarrhal laryngitis
    ±Þ¼ºÄ«Å¸¸£Èĵο°
  • acute confusional state
    ±Þ¼ºÈ¥µ·»óÅÂ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • indurative pneumonia =parenchymatous p.
    °æÈ­¼º Æó·Å, ½ÇÁú¼º Æó·Å.
  • acute hepatitis
    ±Þ¼º °£¿°
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • hepatitis,acute viral
    ±Þ¼º¹ÙÀÌ·¯½º¼º
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • Halothane hepatitis
    ÇÒ·Îź°£¿°
  • Hepatitis
    °£¿°(ÊÜæú)
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • amebic hepatitis
    ¾Æ¸Þ¹Ù¼º °£¿°
  • anicteric hepatitis
    ¹«È²´Þ¼º °£¿°.
  • antigen, hepatitis B core
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute hepatitis
    ±Þ¼º °£¿°
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • hepatitis,acute viral
    ±Þ¼º¹ÙÀÌ·¯½º¼º
  • indurative pneumonia =parenchymatous p.
    °æÈ­¼º Æó·Å, ½ÇÁú¼º Æó·Å.
  • parenchymatous
    ½ÇÁú¼º(ãùòõàõ)ÀÇ.
  • parenchymatous cartilage
    ½ÇÁú¼º ¿¬°ñ(ãùòõàõæãÍé).
  • parenchymatous cell
    ½ÇÁú¼¼Æ÷(¡­á¬øà).
  • parenchymatous corneal dystrophy
    °¢¸·½ÇÁúÀÌ¿µ¾ç(Áõ)
  • parenchymatous degeneration
    ½ÇÁúº¯¼º(ãùòõܨàõ)
  • parenchymatous jaundice
    ½ÇÁú¼º Ȳ´Þ.
  • parenchymatous keratitis
    ½ÇÁú°¢¸·¿°
  • parenchymatous mastitis
    ½ÇÁú¼º À¯¹æ¿°.
  • parenchymatous myocarditis
    ½ÇÁú¼º ½É±Ù¿°.
  • parenchymatous myositis
    ½ÇÁú¼º ±Ù¿°.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute porphyria
    ±Þ¼º(Ðáàõ) Æ÷¸£ÇǸ°Áõ (ñø)
  • acute serum
    ±Þä Ç÷û(Ðáóõúìôè)
  • acute test
    ´Ü·® µ¶¼º½ÃÇè (Ó¤ÕáÔ¸àõãËúÐ)
  • hepatitis B surface antigen
    BÇü(úþ) °£¿°(ÊÜæú) Ç¥¸é Ç׿ø(øúØüù÷ê«)
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
  • type B hepatitis
    BÇü(úþ) °£¿°(ÊÜæú)
  • viral hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿° (ÊÜæú)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • parenchymatous
    ½ÇÁú¼ºÀÇ
  • acute
    ±Þ¼º, ¿¹¸®ÇÑ
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute angle
    ¿¹°¢
  • acute stage
    ±Þ¼º±â
  • fulminant hepatitis
    Àü°Ý¼º°£¿°
  • hepatitis
    °£¿°
  • hepatitis B virus
    BÇü °£¿°¹ÙÀÌ·¯½º
  • infectious hepatitis virus
    Àü¿°¼º°£¿°¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
AH abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro...
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
AP accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AAH Acute alcoholic hepatitis
AH Acute hepatitis
AH-B acute hepatitis B
AVH acute viral hepatitis
AIH 1)autoimmune hepatitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute hepatitis
    ±Þ¼º °£¿°
    ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º¡¤½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶¡¤È­Çоàǰ¡¤ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • parenchymatous myelitis
    ½ÇÁú¼º ô
  • parenchymatous myelitis
    ½ÇÁú¼º ô¼ö¿°
  • parenchymatous myositis
    ½ÇÁú¼º ±Ù¿°
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • acute appendicitis£¨±Þ¼º Ãæ¼ö¿°£©

    acute arthritis

    ±Þ¼º °üÀý¿°
    ¿°Áõ°ú °¨¿°°ú ¿Ü»ó¿¡ ÀÇÇÏ¿© µ¿Åë, ¹ß¿­, ¹ßÀû, Á¾Ã¢ÀÌ ½ÉÇÑ °üÀý¿°.
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • cholestatic hepatitis
    ´ãÁó ¿ïü¼º °£¿°, ´ãÁó Á¤Ã¼¼º °£¿°
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • epidemic hepatitis
    À¯Ç༺ °£¿°
  • hepatitis
    °£¿°
    °£ÀÇ ¿°Áõ¼º Áúȯ. °£Àå¿°À̶ó°íµµ ÇÑ´Ù. °£ ÁúȯÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀ¸·Î¼­, Å©°Ô ±Þ¼º °£¿°°ú ¸¸¼º °£¿°À¸·Î ³ª´«´Ù. ¡¼±Þ¼º °£¿°¡½ ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º, ½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶, È­ÇÐ ¾àǰ, ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • hepatitis A
    AÇü °£¿°
    AÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â Àü¼¼°èÀûÀ¸·Î ºÐÆ÷µÈ ÀÚ±â ÇÑÁ¤¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀ¸·Î¼­, À§»ý »óŰ¡ ³ª»Ú°í °æÁ¦ ¼öÁØÀÌ ³·Àº Áö¿ª¿¡ ´õ¿í ¸¹ÀÌ ¹ß»ýÇÏ¸ç ºñ°æ±¸Àû °¨¿°µµ °¡´ÉÇϱâ´Â Çϳª °ÅÀÇ ÀüÀûÀ¸·Î ´ëº¯ °æ±¸ °æ·Î¸¦ ÅëÇÏ¿© ÀüÆÄµÇ°í, º¸±ÕÀÚ »óÅ´ »ý±âÁö ¾Ê´Â´Ù. Àẹ ±â°£Àº 15-20ÀϷμ­ Æò±Õ 30ÀÏÀÌ´Ù. ´ë´Ù¼ö ȯÀÚ´Â ÀÓ»ó Áõ¼¼°¡ ¶Ñ·ÇÇÏÁö ¾Ê°Å³ª °æÇÑ °¨±â Áõ»óÀ» ³ªÅ¸³»¸ç Ȳ´ÞÀº ÀÖ´õ¶óµµ ¸Å¿ì °æ¹ÌÇÏ´Ù. ±¤¹üÀ§ÇÑ °£ ±«»ç°¡ ÀϾ ¼ö ÀÖÀ¸³ª BÇü °£¿°¿¡¼­ º¸´Ù´Â ÈξÀ Àû°Ô ³ªÅ¸³­´Ù.
  • hepatitis B
    BÇü °£¿°
    BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °£ÀÇ ¿°Áõ¼º ÁúȯÀ¸·Î¼­ Àü¼¼°èÀûÀ¸·Î À¯ÇàÇϸç À¯ÇàÀÌ °¡Àå ³ôÀº Áö¿ªÀº Áß°î°ú µ¿³²¾Æ, »çÇ϶ó ÁÖº¯ ¾ÆÇÁ¸®Ä«, ÅÂÆò¾ç±ºµµÀÇ ´ëºÎºÐ ¹× ¾Æ¸¶Á¸ À¯¿ª µîÀÌ´Ù.
  • hepatitis B virus
    BÇü °£¿° ¹ÙÀÌ·¯½º
    1. BÇü °¨¿° ȯÀÚ¿¡¼­ ¸ðµç ü¾× ³»·Î ¹æÃâµÇ´Â ¹ÙÀÌ·¯½º. 2. »ç¶÷ÀÇ °£¿¡ »ì¸ç, Ç÷û °£¿° µîÀ» ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½º. HB ¹ÙÀÌ·¯½º¶ó°íµµ ÇÑ´Ù. HBs Ç׿ø, HBc Ç׿ø, HBe Ç׿ø µî ¼¼ Á¾·ùÀÇ Ç׿ø ´Ü¹éÁúÀ» Áö´Ñ ¹ÙÀÌ·¯½ºÀÌ´Ù. ÀÌ °¡¿îµ¥ HBs Ç׿ø¿¡´Â º¹¼öÀÇ Ç׿ø °áÁ¤±â°¡ ÀÖ¾î, ±× ¦¸ÂÃã¿¡ µû¶ó BÇü °£¿° ¹ÙÀÌ·¯½º´Â adr, adw, ayr, aywÀÇ 4°¡Áö ¾ÆÇüÀ¸·Î ³ª´©¾îÁ® ÀÖ´Ù. 1965³â ¹Ì±¹ÀÇ S. ºí·³¹ö±×°¡ ¿À½ºÆ®·¹Àϸ®¾Æ ¿øÁÖ¹ÎÀÇ Ç÷û¿¡¼­ ¹ß°ßÇÏ¿© ´çÃÊ¿¡´Â Ç׿ø¼ºÀÌ ÀÖ´Â ¹°ÁúÀ̶ó°í º¸°í, HB Ç׿ø ¶Ç´Â ¿À½ºÆ®·¹Àϸ®¾Æ Ç׿øÀ̶ó°í ºÒ·¶´Ù. ±× ÈÄ DNA
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
acute parenchymatous hepatitis A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice.
Synonym: acute parenchymatous hepatitis, Rokitansky's disease.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
parenchymatous Relating to the parenchyma.
Synonym: parenchymal.
(05 Mar 2000)
parenchymatous cartilage An embryonic or immature stage of cartilage in which it consists chiefly of cells with very little matrix.
Synonym: parenchymatous cartilage.
(05 Mar 2000)
parenchymatous cell of corpus pineale A cell of the pineal body with long processes ending in bulbous expansions. Pinealocytes receive a direct innervation from sympathetic neurons that form recognizable synapses. The club-shaped endings of pinealocyte processes terminate in perivascular spaces surrounding capillaries.
Synonym: chief cell of corpus pineale, parenchymatous cell of corpus pineale.
Origin: pineal + G. Kytos, cell
(05 Mar 2000)
parenchymatous degeneration Swelling of cells due to injury to the membranes affecting ionic transfer; causes an accumulation of intracellular water.
Synonym: albuminous swelling, granular degeneration, hydropic degeneration, parenchymatous degeneration.
(05 Mar 2000)
parenchymatous goiter A form of goiter in which there is a great increase in the follicles with proliferation of the epithelium.
Synonym: follicular goiter.
(05 Mar 2000)
parenchymatous haemorrhage Bleeding into the substance of an organ.
(05 Mar 2000)
parenchymatous mastitis Inflammation of the secreting tissue of the breast.
Synonym: glandular mastitis.
(05 Mar 2000)
parenchymatous neuritis Inflammation of the nervous substance proper, the axons, and myelin.
Synonym: axial neuritis, central neuritis.
(05 Mar 2000)
anicteric hepatitis Hepatitis without jaundice.
(05 Mar 2000)
anicteric virus hepatitis A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis.
(05 Mar 2000)
autoimmune hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
vaccination, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
vaccineation, serum hepatitis See Vaccination, hepatitis b.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • parenchymatous
  • acute
    ³¯Ä«·Î¿î; °Ý·ÄÇÑ
  • acute
    ³¯Ä«·Î¿î;»ÏÁ·ÇÑ;¿¹¹ÎÇÑ;ºóÆ´¾ø´Â;°Ý·ÄÇÑ;±Þ¼ºÀÇ
  • hepatitis
    °£¿°
  • hepatitis A
    AÇü °£¿°;Àü¿°¼º(Ç÷û)°£¿°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á